Medtronic Inc. has announced plans to work with drug company Novo Nordisk in the diabetes management space, according to a statement from the companies on Sept. 16. Medtronic, a medical technology company, has its headquarters in Dublin but its insulin pump division is based in Northridge. Novo, based in Denmark, produces insulin and manufactures diabetic devices. Medtronic plans to incorporate Novo’s insulin dosing data, used in the company’s forthcoming smart insulin pens, into its own Continuous Glucose Monitoring devices such as the Guardian Connect system. Novo insulin pens are set to be released next year. “Our new agreement with Novo Nordisk, the world’s largest producer of insulin, will streamline the sharing of two of the most important pieces of information – glucose measurements and insulin dosed,” Alejandro Galindo, president of the advanced insulin management division at Medtronic, said in a statement. “With this, Medtronic can further enhance our market-leading analytics and insights to help ease the burden of diabetes.” The global diabetes care market is expected to reach a value of $95.1 billion by 2023, according to Research and Markets.com.
